May 16th 2024
Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.
April 30th 2024
Your daily dose of the clinical news you may have missed.
April 22nd 2024
Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.
April 18th 2024
Your daily dose of the clinical news you may have missed.
April 11th 2024
In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.
COVID-19 Vaccine Update: FDA Amends Pfizer, Moderna EUAs, Simplifying Use of Bivalent Formulations
April 18th 2023The FDA action ends the use of monovalent COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna in favor of bivalent formulations to simplify the vaccination schedule, said the Agency.
Investigational Oral Antiviral Ensitrelvir Reduces Time to Resolution of Common COVID-19 Symptoms
April 10th 2023Recent research shows that patients with mild-to-moderate COVID-19 who received ensitrelvir within 5 days of symptom onset saw their symptoms resolve a day earlier than those who received placebo.
2 Commerce Drive
Cranbury, NJ 08512